Clinician reference tool — not medical advice. This is a clinical decision-aid intended for healthcare professionals: it gives deterministic suggestions to think with, not a diagnosis or a prescription. If you’re a patient, you’re welcome to look around — but please review anything here with your own doctor; it isn’t a substitute for personalized medical care.

Evidence: NICE NG23 — Menopause: identification and management (201… 2024 · sources last checked 2026-08-20

Reference tool — not medical advice. Thresholds, targets, and first-line agents differ by guideline body and change over time — switch the lens to compare. Clinician judgement, dosing/monitoring, contraindications, and live coverage always required. Runs entirely in your browser — no data is collected.

Menopause / MHT selector

Choose the guideline lens (SOGC/CAMS / Menopause Society / NICE), the indication, uterus status, timing and contraindications — get the recommended approach: transdermal estradiol (+ micronized progesterone if uterus present), low-dose vaginal estrogen for isolated GSM, or a non-hormonal option. Safety-gated (breast cancer, VTE, migraine-with-aura).

Guideline lens

Predominant indicationchoose one

Uteruschoose one

Determines whether a progestogen is required

Timing (age / years since menopause)choose one

The 'timing hypothesis'

Contraindications to systemic MHT

Risk modifiers

Recommended approach

Systemic MHT — TRANSDERMAL estradiol (estrogen alone — no uterus)

Notes

  • • No arbitrary stopping age — reassess benefit-risk at each review and continue while benefits outweigh risks.

Suggested drug classesPer SOGC / CAMS 2021.

Select the predominant indication and uterus status to begin.

Key rules: transdermal estradiol is the lower-risk systemic route; isolated GSM → vaginal estrogen; migraine-with-aura is NOT an absolute contraindication (use transdermal).

Should I be tested?

Last reviewed 2026-09-23

Static, reviewed content for patients and NDs who ask whether a blood test can confirm or rule out menopause-related concerns. Supports, does not replace, clinical assessment.

"Should I be tested?" for perimenopause/menopause

Defined testing criteria

Also called: perimenopause testing, menopause blood test, hormone testing for menopause, am I in menopause, FSH test menopause

Patients wonder whether a blood test can confirm perimenopause or menopause, especially when their symptoms or period pattern are irregular, or when an ND has ordered a hormone panel. It's a reasonable question: hormone levels genuinely fluctuate a great deal during perimenopause, which is exactly why guidelines set clear rules for when testing helps and when it just adds noise.

Raises suspicion

  • • Age under 45 with menopause-type symptoms or amenorrhea, to help establish the cause
  • • Age under 40 with menopause-associated symptoms and an elevated FSH confirmed on 2 samples 4-6 weeks apart: supports premature ovarian insufficiency (POI)
  • • An atypical picture where the diagnosis is genuinely unclear: for example, hysterectomy without oophorectomy removing the usual marker (periods)

Does not raise suspicion

  • • Age 45 or older with typical vasomotor symptoms and menstrual-pattern change: diagnosis is by symptoms and menstrual history alone, no blood test needed
  • • Wanting a single hormone level for reassurance or certainty: levels fluctuate too much during perimenopause for one result to be reliable
  • • Using combined hormonal contraception or high-dose progestogen: FSH is not reliable for identifying menopause in this situation anyway

Red flags

  • • Postmenopausal bleeding, or bleeding after sex, at any age: needs prompt gynecologic assessment, not hormone testing

Who to test

  • Amenorrhea or menopause-type symptoms under 45, especially under 40: FSH (follicle-stimulating hormone) (Situation-specific), Estradiol (E2) (Situation-specific)FSH elevated on 2 samples 4-6 weeks apart, together with a low estradiol, supports premature ovarian insufficiency; a single result is not enough to diagnose it.
  • Woman 45 or older with typical symptoms and menstrual patternNo blood test needed; diagnosis is clinical, from symptoms and menstrual history.

More likely instead

  • • typical perimenopause (needs no confirmatory test)
  • • thyroid dysfunction
  • • pregnancy
  • • hyperprolactinemia (if galactorrhea present)

Counselling script

“If you're over 45 with typical symptoms, we don't need a blood test to diagnose menopause — your history is enough on its own. If you're younger than that, or your periods stopped unusually early, checking FSH and estradiol on two occasions can help confirm premature ovarian insufficiency. Without early or unusual symptoms, a hormone panel won't add anything useful, since levels fluctuate too much to read on their own.”

Chart snippet (OSCAR-safe plain text)

Concern discussed, not tested

Concern re: perimenopause/menopause diagnosis discussed, patient or ND raised hormone testing.
Discriminating features: age under 45, amenorrhea, or POI risk factors; reviewed.
Red flags: postmenopausal bleeding or bleeding after sex; absent.
Assessment: age 45+ with typical symptoms, diagnosis is clinical and no hormone testing is needed; if under 45 or atypical, FSH/estradiol may help.
Plan: hormone testing not ordered given age and typical presentation.
Ref: NICE NG23 2026; Canadian Menopause Society diagnosis hub.
Patient given info page: https://menopause.ajaxharwoodclinic.com/patient
Revisit if: postmenopausal bleeding, bleeding after sex, or symptoms atypical for age develop.

Testing ordered

Concern re: perimenopause/menopause diagnosis discussed.
Discriminating features: amenorrhea or symptoms under age 45; red flags absent.
Assessment: age or presentation atypical enough to warrant hormone testing.
Plan: FSH and estradiol ordered; repeat FSH 4-6 weeks later if premature ovarian insufficiency being considered.
Ref: NICE NG23 2026; Canadian Menopause Society diagnosis hub.
Patient given info page: https://menopause.ajaxharwoodclinic.com/patient
Revisit if: postmenopausal bleeding, bleeding after sex, or results do not fit the clinical picture.

Revisit if

  • • Postmenopausal bleeding or bleeding after sex develops
  • • Symptoms are atypical for age, or persist despite treatment
  • • A single FSH result in a woman under 40 needs confirmation on a second sample 4-6 weeks later before diagnosing POI

References

  1. 1. NICE. Menopause: identification and management (NG23) (published 2015, last updated 15 April 2026) (2026)Lists tests, including FSH and estradiol, not to use to identify perimenopause or menopause in people 45 or over
  2. 2. Canadian Menopause Society. Diagnosis and Management (Menopause HUB) (2026)States menopause diagnosis is primarily clinical, based on age, menstrual history and symptoms, with hormone testing only in specific situations
  3. 3. Society of Obstetricians and Gynaecologists of Canada / Choosing Wisely Canada. Obstetrics and Gynaecology recommendations (2021)Recommends against routinely ordering hormone levels including estradiol, progesterone, FSH and LH in postmenopausal women or after hysterectomy
Evidence notes

Tag rationale: A, not borderline. Perimenopause/menopause has a clean, guideline-stated testing rule: no test needed at typical age with typical symptoms (NICE NG23; CMS Hub), versus a defined FSH/estradiol-based pathway for premature ovarian insufficiency under 40 and amenorrhea work-up under 45. This is consistent with, and extends, the existing ahc-menopause patient door, which already states 'blood tests are usually not needed to diagnose menopause in someone over about forty-five with typical symptoms' but says nothing about the under-45/POI exception; this record adds that without contradicting the existing claim. No new sources were needed; all three references were already verified in the registry from earlier test batches (estradiol, progesterone, fsh test records).

Popular labels: what they mean

"Estrogen dominance" / "progesterone deficiency"

Not a recognized medical diagnosis

Also called: estrogen dominance, progesterone deficiency, hormone imbalance, unopposed estrogen

Popularized by wellness sources and some NDs using salivary or dried-urine hormone panels, 'estrogen dominance' is offered as an explanation for PMS-type symptoms, weight gain, mood changes, or heavy periods, especially in perimenopause. The underlying observation isn't unreasonable: progesterone often falls before estrogen does during perimenopause. But 'estrogen dominance' as a lab-confirmed diagnosis with its own treatment protocol is not something current guidelines recognize, mainly because the tests used to 'confirm' it are not validated for that purpose.

Raises suspicion

  • • This label has no validated discriminating features or diagnostic test of its own
  • • Heavy or irregular bleeding, or significant mood or physical symptoms, deserve assessment on their own terms (structural causes, thyroid, mood disorder), not as 'estrogen dominance'

Does not raise suspicion

  • • Ordinary PMS-type symptoms or perimenopausal mood and weight changes
  • • A salivary or dried-urine hormone panel reporting an abnormal estrogen-to-progesterone ratio: these assays are not standardized or validated for this purpose

Red flags

  • • Heavy menstrual bleeding causing anemia, postmenopausal bleeding, or bleeding after sex: needs its own gynecologic work-up, not hormone-ratio testing

Who to test

More likely instead

  • • typical perimenopausal hormone fluctuation (managed by symptom, not by ratio)
  • • PMS or PMDD
  • • heavy menstrual bleeding from a structural cause (fibroids, polyps)
  • • Hypothyroidism
  • • Depression or anxiety

Counselling script

“Saliva and urine hormone tests aren't standardized, so a result showing 'estrogen dominance' doesn't reliably tell us what your hormones are actually doing. It's true progesterone often falls before estrogen in perimenopause, and that shift can cause real symptoms, but it doesn't need a special lab-confirmed diagnosis to treat. Let's focus on your specific symptoms instead, and check for other explanations like thyroid problems or a bleeding cause if that fits.”

Chart snippet (OSCAR-safe plain text)

Concern discussed, not tested

Concern re: 'estrogen dominance'/hormone imbalance discussed, raised by patient or ND, often based on a salivary or dried-urine hormone panel.
Discriminating features for a distinct diagnosis: absent.
Assessment: 'estrogen dominance' as a lab-confirmed diagnosis is not supported; salivary/urine hormone panels are not standardized for this use. Normal perimenopausal progesterone-before-estrogen shift discussed as the likely explanation.
Plan: no salivary or urine hormone panel ordered; alternative causes (thyroid, structural bleeding cause, mood) considered as indicated.
Ref: NAMS 2022 hormone therapy position statement; NICE NG23 2026.
Patient given info page: https://menopause.ajaxharwoodclinic.com/patient
Revisit if: heavy bleeding, postmenopausal bleeding, or bleeding after sex develops.

Revisit if

  • • Heavy menstrual bleeding, postmenopausal bleeding, or bleeding after sex develops
  • • Symptoms significantly impair function despite reassurance and standard management
  • • Suspicion arises for a distinct condition (thyroid disease, a structural bleeding cause)

References

  1. 1. The Menopause Society (NAMS). The 2022 Hormone Therapy Position Statement of The North American Menopause Society (2022)States salivary and urine hormone testing to determine dosing are unreliable and not recommended
  2. 2. Society of Obstetricians and Gynaecologists of Canada / Choosing Wisely Canada. Obstetrics and Gynaecology recommendations (2021)Recommends against routinely ordering hormone levels in postmenopausal women or after hysterectomy
  3. 3. NICE. Menopause: identification and management (NG23) (published 2015, last updated 15 April 2026) (2026)Lists tests, including progesterone and estradiol, not to use to identify perimenopause or menopause in people 45 or over
Evidence notes

Tag rationale: C, not borderline, for the packaged 'estrogen dominance' diagnosis-and-protocol construct built on salivary/urine testing. The underlying physiology it references (relative progesterone deficiency as estrogen and progesterone both decline unevenly in perimenopause) is real and not disputed here; what's not validated is turning that into a lab-confirmed label with its own treatment protocol, when the labs used (salivary/urine panels) are explicitly called unreliable by NAMS 2022. Gap: no dedicated peer-reviewed source was found in this session specifically titled around debunking the term 'estrogen dominance' itself (searched); the case here rests on the invalidity of the tests used to 'confirm' it plus the absence of any validated diagnostic criteria for the label, which is recorded as a gap rather than treated as separately settled. Host is 'menopause' per batch instruction.

Guidelines

References

  1. [1]SOGC + Canadian Menopause Society. Guideline No. 422 series (Menopause), JOGC 2021-2022 (Canadian backbone). link
  2. [2]The Menopause Society. 2022 Hormone Therapy Position Statement (Menopause 2022;29:767) and 2023 Nonhormone Therapy Position Statement. link
  3. [3]NICE NG23 — Menopause: identification and management (2015, updated 2024). Transdermal preferred with VTE risk (BMI >30); Vinogradova et al. BMJ 2019 (oral estrogen VTE risk). link